axsomelogo-468x57.jpg
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month
07 mai 2021 07h00 HE | Axsome Therapeutics, Inc.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month,...
Timberline Knolls Celebrates National Mental Health Awareness Month
06 mai 2021 16h08 HE | Timberline Knolls
Chicago, May 06, 2021 (GLOBE NEWSWIRE) -- For many individuals, the pandemic has made it difficult to feel connected to our communities, families and friends. There has been an increase in the...
87520785_101152591495741_6497961433500745728_o.jpg
UPDATE -- Mycotopia Therapies Inc. Begins Trading Under Symbol TPIA
04 mai 2021 10h15 HE | Mycotopia Therapies Inc.
MIAMI, May 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc., (OTC Pink: TPIA), a company focused on psychedelic therapies, announced today its name and symbol change are complete. Mycotopia...
Using Rapid-Acting Brain Stimulation for Treatment-Resistant Depression - A Free Webinar from the Brain & Behavior Research Foundation
04 mai 2021 09h00 HE | Brain & Behavior Research Foundation
New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Using Rapid-Acting Brain Stimulation for Treatment-Resistant Depression” on...
87520785_101152591495741_6497961433500745728_o.jpg
Mycotopia Therapies Inc. Begins Trading Under Symbol MYCO
04 mai 2021 07h30 HE | Mycotopia Therapies Inc.
MIAMI, May 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc., (OTC Pink: MYCO), a company focused on psychedelic therapies, announced today its name and symbol change are complete. Mycotopia...
logo.png
Nexstim Receives an NBT® System Order from a New Therapy Customer in Finland
29 avr. 2021 03h00 HE | Nexstim Oyj
Press Release, Helsinki, 29 April 2021 at 10:00 AM (EEST) Nexstim Receives an NBT® System Order from a New Therapy Customer in Finland Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
26 avr. 2021 06h00 HE | Axsome Therapeutics, Inc.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...
logo.png
Nexstim Plc Business and Clinical Update Q1 2021
22 avr. 2021 05h00 HE | Nexstim Oyj
Press release, Helsinki, 22.04.2021, 12.00 pm (EEST) Nexstim Plc Business and Clinical Update Q1 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of...
logo.png
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD
16 avr. 2021 05h00 HE | Nexstim Oyj
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX,...
compass_positive_tagline-01.png
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
15 avr. 2021 03h00 HE | COMPASS Pathfinder Ltd.
London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...